An independent intelligence board aggregating credible research, preprints, clinical findings, biohacking experiments, and community discussions on therapeutic peptides, longevity science, and evidence-based anti-aging. Stories are scored for relevance, credibility, novelty, momentum, and practicality so the most important findings surface first.
A writer dug into the actual scientific papers on five popular "peptide nootropics" — Semax, Selank, DSIP, Cerebrolysin, and Adamax — and found they are not equally supported by research. Online discussions often treat them as if they’re interchangeable brain boosters, but the published studies vary a lot in quality and quantity. The writer ranked them roughly from best-studied to least-studied and highlighted differences in study design, sample sizes, independent replication, and who paid for the work. Semax and Selank are small, lab-made versions of natural peptides (short proteins) that were developed and studied primarily in Russia. They’re usually given as nasal sprays and are claimed to affect stress, attention, and mood. Cerebrolysin is a mixture of peptide fragments derived from pig brain tissue and is used in some countries as a treatment for stroke and cognitive decline. DSIP (Delta Sleep-Inducing Peptide) was identified for its sleep-related effects, and Adamax is a less-known peptide often discussed in online nootropic circles. In plain terms: these are not vitamins or typical drugs — they’re short chains of amino acids designed to nudge brain systems, but each one has a different origin and proposed effect. What the literature actually shows is mixed. Semax and Selank have the most published work, including some clinical trials and experimental studies suggesting modest benefits for attention, anxiety, or recovery after brain injury — but many studies are small, done in a single country, or lack independent replication. Cerebrolysin has clinical trials for stroke and dementia with larger patient groups, and some positive signals, but results vary and regulatory approval is limited by inconsistent evidence. DSIP and Adamax have very sparse, low-quality, or preliminary data; for DSIP, the sleep effects sometimes show up in animal studies but human evidence is weak. Overall, effect sizes in human studies tend to be modest when present, and for several of these peptides the evidence comes from a few researchers or from industry-funded work, which raises the need for cautious interpretation. Why this matters: if you’re curious about using these peptides to boost cognition, mood, or recovery, the research doesn’t support treating them as a single category of proven brain enhancers. People considering them should know that Semax and Selank are the best-studied options in this group, while Cerebrolysin has some clinical trial history but mixed results. DSIP and Adamax are mostly experimental. That matters for expectations — these aren’t guaranteed fixes — and for cost, sourcing, and medical oversight, since outcomes and quality control vary. There are important caveats and risks. Many studies are small, short-term, or not replicated by independent teams. Safety data is limited for long-term use, dosing is not standardized, and manufacturing quality can vary — especially for products bought online. Some of these peptides are only approved or commonly used in certain countries and may not have regulatory approval elsewhere. People with medical conditions, pregnant or breastfeeding individuals, and those on multiple medications should avoid experimenting without a doctor’s guidance. In short: promising signals exist for a couple of these peptides, but the gap between hype and rigorous evidence is real. Bottom line: Semax and Selank have the most solid but still limited research; Cerebrolysin shows mixed clinical results; DSIP and Adamax are under-studied — don’t assume they’re interchangeable or proven nootropics.
Source: r/Nootropics